GeneDx Holdings (WGS) Current Deferred Revenue (2020 - 2022)

GeneDx Holdings (WGS) has reported Current Deferred Revenue for 3 consecutive years, with $40000.0 the latest figure, recorded in Q4 2022.

• In Q4 2022, Current Deferred Revenue fell 91.54% year-over-year to $40000.0; the TTM figure through Dec 2022 stood at $40000.0 (down 91.54% YoY), while the FY2022 annual figure was $40000.0, down 91.54% from the prior year.
• Current Deferred Revenue eased to $40000.0 in Q4 2022 per WGS's latest filing, from $66000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $2.8 million in Q1 2021 and bottomed at $40000.0 in Q4 2022.
• Historically, Current Deferred Revenue has averaged $1.0 million across 3 years, with a median of $493000.0 in 2021.
• Annual changes were most pronounced in 2021 — Current Deferred Revenue plunged 73.47% — and 2022, when it sank 97.65%.
• GeneDx Holdings' Current Deferred Revenue stood at $1.8 million in 2020, then plunged by 73.47% to $473000.0 in 2021, then plunged by 91.54% to $40000.0 in 2022.
• Business Quant data shows WGS's Current Deferred Revenue at $40000.0 in Q4 2022, $66000.0 in Q1 2022, and $473000.0 in Q4 2021.